Introduction
============

Coronary tone is a finely tuned parameter as blood supply to the heart is necessary for survival and its cardiovascular diseases. Several intrinsic factors and agents control the coronary tone by acting via endothelial cells (EC) or directly on smooth muscle cells (SMC). Changes in cytosolic Ca^2+^ concentration (\[Ca^2+^\]i) in SMC and EC are pivotal to regulation of coronary tone. An increase in \[Ca^2+^\]i in EC and SMC has opposite effects on vascular contractility. In EC, an increase in \[Ca2+\]i activates nitric oxide synthase (eNOS) with a consequent increase in production of NO, which causes SMC to relax by activating guanylate cyclase \[[@b12]\]. In EC eNOS is localized on the plasma membrane (PM) and its activation has a paracrine function. In contrast, in SMC \[Ca^2+^\]i increases transiently and then decreases in contractile cycle.

The increased \[Ca^2+^\]i activates calcium calmodulindependent myosin light chain kinase, leading to increased phosphorylation of the 20 kD myosin light chains, cross-bridge formation between the myosin heads and the actin filaments and eventually SMC contraction \[[@b20]\]. The contractile filaments are not just located at the surface but may also be deeply embedded in the cell. Since, EC and SMC are vastly different in their structure and function, it is logical that they would require different pathways to lower \[Ca^2+^\]i.

\[Ca^2+^\]i is maintained in EC and SMC at low levels: it increases during cell excitation and is then restored to normal levels. The excess \[Ca^2+^\]i following stimulation may be resequestered by the sarco-/endoplasmic reticulum Ca^2+^ ATPases (SERCA) into the reticulum or expelled from the cell by the plasma membrane Ca^2+^ ATPases (PMCA) and the Na^+^--Ca^2+^ exchangers (NCX) \[[@b2]\]. Each of these transporters is encoded by different genes whose transcripts may be alternatively spliced thus giving a large milieu of pathways for lowering \[Ca^2+^\]i. Each pathway differs in its role and modes of regulation \[[@b4]\]. SERCA are encoded by three genes (SERCA1--3) with the SERCA2 splice SERCA2b being most widely distributed \[[@b29]\]. SERCA3 lacks the site for phospholamban regulation present in SERCA2. PMCA are encoded by four genes (PMCA1--4), however, alternative splicing gives over 30 possible isoforms that differ in regulation by protein kinases and calmodulin and to some degree in Ca^2+^ kinetics \[[@b4]\]. PMCA1 and 4 are the most ubiquitously expressed isoforms. NCX are encoded by the genes NCX1--3 of which NCX1 is widely expressed and shows extensive alternative splicing \[[@b21]\]. Although both PMCA and NCX can expel Ca^2+^, they differ in this role. PMCA has a higher affinity for Ca^2+^ than does NCX. In contrast, it is not clear that the higher affinity enables PMCA to remove more cytosolic Ca^2+^ than does NCX \[[@b24]\]. PMCA works only as a Ca^2+^ extrusion system but NCX may also allow Ca^2+^ entry depending on electrochemical gradients of Na^+^ and Ca^2+^. Studies in cardiac function on Ca^2+^ transporters have been useful in developing appropriate therapeutic strategies in cardiovascular diseases. Here, we compare EC and SMC from pig coronary artery for activities, protein abundance and isoform expression of PMCA, SERCA and NCX. Based on the comparison, we present a composite picture for the roles of PMCA, NCX and SERCA in the function of EC and SMC. To our knowledge, such a comparison has not been made previously.

Materials and methods
=====================

Membrane isolation
------------------

Pig heart and brain were obtained from local abattoirs. PM-enriched fractions were isolated by differential centrifugation followed by sucrose density gradient centrifugation as described previously \[[@b17]\]. Alternatively, coronary artery EC and SMC were cultured and then used for PM isolation \[[@b16]\]. Aliquots were stored at −80°C.

RNA isolation and RT-PCR
------------------------

In most experiments, SMC and EC cultured from pig coronary artery were used \[[@b16]\]. The cultured EC were tested using immunocytochemistry and found to be positive for von Willebrand factor and eNOS and negative for α-actin. SMC were positive for α-actin and negative for von Willebrand factor and eNOS. RNA was isolated using a total RNA isolation kit (Qiagen, Mississauga, ON, USA). The isolated RNA was DNase I digested and reverse transcribed using the ThermoScript RT-PCR system (Invitrogen, Burlington, ON), following instructions of the manufacturer. In initial experiments, the conditions for PCR were optimized for each primer set and template. Routinely, PCR was carried out with AmpliTaq (Applied Biosystems, Foster City, CA, USA) at 2.5 mM MgCl~2~. Primers are given in [Table 1](#tbl1){ref-type="table"}. A typical PCR cycle consisted of denaturation at 94°C for 40 sec, annealing at 58°C (PMCA), 60°C (NCX), 66°C (phospholemman) for 40 sec, and extension at 72°C for 50 sec. After 30 cycles, the reaction at 72°C was continued for another 5 min.

###### 

Sequences of primers used for RT-PCR

                     **5′--3′**                 **Position**   **Genbank accession No.**
  ------------------ -------------------------- -------------- ----------------------------
  PMCA1 up           TAGGCACTTTTGTGGTACAG       3041           Pig PMCA1 NM_214352
  PMCA1 dn           GGCTCTGAATCTTCTATCCTA      3470           Pig PMCA1 NM_214352
  PMCA4 up           CCCAGCCAGCACTATACCATT      3750           Human PMCA4 NM_001684
  PMCA4 dn           TGTAGAGAGCTGTCCGACTGG      4480           Human PMCA4 NM_001684
  PMCA4a up          CCCAGCCAGCACTATACCATT      3750           Human PMCA4 NM_001001396
  PMCA4a dn          AAAGAGGCTCCCGTCTGGAAT      4231           Human PMCA4 NM_001001396
  NCX1 up            GCATTGGCATCATGGAGGTGAA     1735           Human NCX1 NM_021097
  NCX1 dn            TTGCTGGTCAGTGGCTGCTTGT     2152           Human NCX1 NM_021097
  Phospholemman up   ATGGCACCTCTCCACCACATCTTG   1              Human phospholemman U72245
  Phospholemman dn   TACCGCCTGCGGGTGGACAGAC     278            Human phospholemman U72245
  G3PDH up           CACGGTCAAGGCTGAGAA         242            Rabbit G3PDH L23961
  G3PDH dn           CGACCTGGTCCTCGGTGTA        912            Rabbit G3PDH L23961

The upstream primers are indicated as up and the starting position of the sequence is given. The downstream primers are indicated as dn and the end position is given.

Western blot analysis
---------------------

Different amounts of protein (between 1 and 50 μg) of the PM-enriched fraction were electrophoresed on 7.5% SDS-polyacrylamide gels and then electroblotted onto a nitrocellulose membrane in transfer buffer containing 0.05% SDS. The membrane was treated with a blocking solution containing 5% (w/v) non-fat dry milk in a tris buffer \[in mM: 10 mM Tris, 140 mM NaCl, and 0.1% (v/v) polyoxyethylene 20 sorbitan monostearate, pH = 7.4\] overnight at 4°C. The blots were incubated with primary antibodies diluted in the tris buffer and 2% (w/v) non-fat dry milk at 22--24°C for 1 hr. Mouse monoclonal anti-PMCA antibody (5F10) and rabbit polyclonal anti-PMCA1 antibody were from Affinity-BioReagents (Golden, CO, USA); mouse monoclonal anti-PMCA4 (JA9) were from Sigma-Aldrich (Oakville, ON) and mouse monoclonal anti-NCX (R3F1) was from Swant (Bellinzona, Switzerland). After incubation, membrane was washed in the tris-buffer and then incubated with horseradish peroxidase-conjugated secondary antibody diluted in the tris buffer and 2% (w/v) non-fat dry milk. The blots were washed in the tris buffer for 1.5 hr. Bands were visualized using an Enchanced Chemiluminiscence Kit (GE Healthcare BioSciences Inc., Baie d\'Urfé, Quebec, Canada) following instructions of the manufacturer.

Biochemical assays
------------------

Ca^2+^-Mg^2+^-ATPase assays for PMCA were performed on the PM-enriched fractions in a coupled enzyme assay that monitored the disappearance of fluorescence of NADH, as described previously \[[@b5]\].Thapsigargin, ouabain and Na-azide were included in these assays to inhibit other ATPases. The difference between the total ATPase and the basal Mg^2+^-ATPase was the Ca^2+^-Mg^2+^-ATPase. SERCA-mediated ^45^Ca^2+^ uptake was examined in saponin-permeabilized EC and SMC as described previously in solutions containing an ATP-regenerating system, Mg^2+^, oxalate (to increase retention of Ca^2+^ in the sarco-/endoplasmic reticulum, Na-azide (to inhibit mitochondrial uptake) in the absence or presence of 2 μM of the SERCA inhibitor thapsigargin \[[@b35]\]. The difference in the uptake with and without thapsigargin was designated as the SERCA pump activity. NCX-mediated ^45^Ca^2+^ uptake was examined using Na^+^-loaded cells in media containing Na^+^ or N-methylglucamine to substitute for Na^+^, as previously described \[[@b8]\].The difference in Ca^2+^ uptake in the two solutions was defined as the NCX-mediated uptake.

Data analysis
-------------

Band intensities of ethidium bromide-stained gels and Western blots were analyzed using Kodak 1D Image Analysis Software. All the values are mean ±S.E.M. of 3--6 replicates. Statistical significance was determined using Student\'s t-test, and values of P \< 0.05 were considered to be significant.

Results
=======

Phenotypes of the cultured EC and SMC used have been reported previously \[[@b7]\]. Cultured EC react positively to the endothelial markers anti-eNOS and anti-von-Willebrand factor, but not to the smooth muscle marker anti-α-actin. Similarly, SMC react positively to anti-α-actin but not to anti-eNOS and anti-von-Willebrand factor.

PMCA in EC and SMC
------------------

RT-PCR was used to determine the PMCA genes expressed in EC and SMC ([Fig. 1](#fig01){ref-type="fig"}). All the primers flanked the cryptic splice site C that lies within PMCA regulatory domain \[[@b39]\]. Sequences of the primers are given in [Table 1](#tbl1){ref-type="table"}. The heart and brain cDNA was used to optimize PCR conditions. PCR products for PMCA2 and 3 were not observed in EC or SMC. Expected sizes for PMCA1b, PMCA4a and PMCA4b were 429, 902 and 727 bp, respectively. Although RT-PCR using RNA from EC gave bands for both PMCA1b and 4b, in co-PCR experiments PMCA1b band dominated. In contrast, bands for both PMCA1 and PMCA4 were observed in co-PCR experiments using different dilutions of the reverse transcripts prepared from SMC ([Fig. 1](#fig01){ref-type="fig"}). These results are consistent with those previously reported using freshly iso-lated EC and SMC from pig aorta \[[@b7]\]. Although not shown, the following controls gave no PCR products: no reverse transcriptase and no cDNA template. Identities of PMCA1b and PMCA4b bands were also confirmed by the sequencing of gel-purified PCR products. Specificity of the PMCA4a was confirmed by RT-PCR with PMCA4a specific primers ([Table 1](#tbl1){ref-type="table"}).

![PMCA expression in pig coronary artery SMC and EC. PCR was carried out using PMCA1 and PMCA4 specific primers as indicated or as co-PCR using both sets of primers. Two different dilutions of reverse transcripts were used for co-PCR of each sample.](jcmm0011-0129-f1){#fig01}

The relative abundance of PMCA proteins was determined using three different antibodies: one that recognized all PMCA isoforms (5F10), anti-PMCA4 (JA9) and a polyclonal anti-PMCA1 antibody. [Figure 2A](#fig02){ref-type="fig"} shows the results of the Western blot using 5F10 in one experiment. Both SMC and EC gave a band at 140 kDa corresponding to PMCA. Thus, the PMCA protein abundance based on [Figure 2B](#fig02){ref-type="fig"} in EC was 22 ±2% of that in SMC. In similar experiments using the anti-PMCA1 antibody, the abundance in EC was 27 ±4% of that in SMC. In contrast, PMCA4 in EC was much smaller (8 ±1% of the SMC value). These results are consistent with those of the PCR experiments in [Fig. 1](#fig01){ref-type="fig"} in that EC express mainly PMCA1.

![PMCA activity and protein abundance in PM-enriched fractions of EC and SMC. **A.** Western blot showing relative protein abundance with the anti-body 5F10 (recognizes all PMCA isoforms). **B.** A plot of pixel volumes (intensity × area) *versus* proteinamount for bands shown in A. Linear regression gave a slope of 21.7 ± 1.6 for SMC and 4.3 ± 0.2 for EC. The linear correlation coefficients for SMC and EC were 0.9820 and 0.9944, respectively. **C.** Relative values of PMCA activity and protein abundance with 5F10 (total PMCA), anti-PMCA4 and anti-PMCA1 in Western blots. The relative value for each parameter was computed taking the mean value in SMC as 100%.](jcmm0011-0129-f2){#fig02}

PMCA activity was measured in PM-enriched fractions isolated from SMC and EC as Ca^2+^-stimulated hydrolysis of ATP in a coupled enzyme assay containing calmodulin and the following inhibitors of other ATPases: sodium azide (mitochondrial Ca^2+^ATPase), ouabain (Na^+^-K^+^-ATPase) and thapsigargin (SERCA). PMCA activity was lower in EC (0.3 ±0.1 nmol/min/mg protein) than in SMC (1.1 ±0.2 nmol/min/mg protein). Thus, PMCA activity in PM-enriched EC fractions was 27 ±9% of that in SMC ([Fig. 2C](#fig02){ref-type="fig"}). These PMCA activity results are consistent with the values of abundance of total PMCA obtained in Western blots ([Fig. 2C](#fig02){ref-type="fig"}).

SERCA in EC and SMC
-------------------

Time course of the ^45^Ca^2+^ uptake by permeabilized EC and SMC with and without thapsigargin is shown in [Fig. 3A](#fig03){ref-type="fig"}. In the presence of thapsigargin, both EC and SMC showed only small ^45^Ca^2+^ uptake but the uptake was much greater in the absence of thapsigargin.The thap-sigargin-sensitive component of the uptake is shown in [Fig. 3B](#fig03){ref-type="fig"}. The SERCA activity in EC (0.15 ±0.05 nmol/min/mg protein) was also lower than in SMC (1.5 ±0.3 nmol/min/mg protein). Thus, the SERCA activity in EC was only 10 ±3% of that in SMC.

![SERCA activity in EC and SMC. **A**. ^45^Ca^2+^ uptake by permeabilized EC or SMC from solutions containing 0 or 2 μM thapsigargin. **B**. SERCA-dependent ^45^Ca^2+^ uptake in EC and SMC defined as difference between the uptake in the absence and presence of thapsigargin determined from A.](jcmm0011-0129-f3){#fig03}

NCX in EC and SMC
-----------------

NCX1 contains six cryptic exons that can result in alternative splicing \[[@b21]\]. Primers flanking the cryptic exons were used to determine the NCX1 iso-forms expressed in EC and SMC ([Table 1](#tbl1){ref-type="table"}). One major (309 bp) and a slightly larger minor band was observed in RT-PCR products of EC and SMC RNA ([Fig. 4A](#fig04){ref-type="fig"}).The two bands were sequenced. Translation of the sequences showed that the 309-bp band corresponded to NCX1.3 and the larger one to NCX1.7. A PM protein, phospholemman, inhibits NCX1 \[[@b42]\].Therefore, we also determined if EC and SMC contain mRNA for this protein. RT-PCR product for phospholemman mRNA (277 bp) was detected in SMC but not in EC. The identity of this band was confirmed by sequencing.

![NCX1 and phospholemman expression in EC and SMC. **A.** RT-PCR using NCX1, G3PDH (glyceraldehyde phosphate dehydrogenase) and PLEM (phospholemman) specific primers. **B.** Western blots with antibody R3F1 showing NCX1 protein abundance.](jcmm0011-0129-f4){#fig04}

NCX1 protein abundance was examined in Western blots using the antibody R3F1 that cross-reacts with all the splices. PM-enriched fractions from EC and SMC were used in this experiment. PM-enriched fraction from EC (20 μg protein) gave an intense doublet at 116 and 112 kD in Western blots but SMC membranes showed very faint bands even with 50 μg protein and none with 20 g ([Fig. 4B](#fig04){ref-type="fig"}). Thus, NCX was more abundant in EC than in SMC.

NCX activity was determined as ^45^Ca^2+^ entry into Na^+^-loaded cells in Na^+^-free solutions. Na^+^-loaded cells (EC or SMC) were placed in normal Na^+^ or in Na^+^ substituted with N-methylglucamine ([Fig. 5A](#fig05){ref-type="fig"}), and the difference in the ^45^Ca^2+^ entry between them was defined as NCX activity ([Fig. 5B](#fig05){ref-type="fig"}). Time course of the uptake in [Figure 5B](#fig05){ref-type="fig"} shows that the NCX-dependent ^45^Ca^2+^ accumulation was linear for 5 min and that the rate of this accumulation was significantly greater in EC than in SMC. This uptake was inhibited by KB-R 7943 and monensin. When examined in several experiments, the NCX activity in EC (0.89 ±0.09 nmol/min/mg protein) was greater than in SMC (0.2 ± 0.01 nmol/min/mg protein). The NCX activity in EC was 447 ± 43% of that in SMC. The greater activity of NCX in EC than in SMC is consistent with the greater NCX1 protein abundance observed in Western blots in [Fig. 4](#fig04){ref-type="fig"}.

![Time course of NCX activity in EC and SMC. A. 45Ca^2+^ uptake by Na^+^-loaded EC or SMC from Na^+^-free and Na^+^-containing solutions. B. NCX-dependent 45Ca^2+^ uptake in EC and SMC defined as difference between the uptake in Na^+^-free and Na^+^-containing solutions in A.](jcmm0011-0129-f5){#fig05}

SERCA, PMCA and NCX activities in EC and SMC
--------------------------------------------

The activities of SERCA, PMCA and NCX were determined using different preparations and hence the absolute activities of the three transporters should not be compared to each other. Therefore, activities of PMCA, SERCA, and NCX in EC are presented as percent of the corresponding values in SMC in [Fig. 6](#fig06){ref-type="fig"}. As shown in [Fig. 6](#fig06){ref-type="fig"}, the PMCA activity was lower in EC than in SMC. SERCA activity in EC was also lower than in SMC. In contrast, NCX activity was much higher in EC than in SMC. Thus, activities of the two Ca^2+^ pumps were lower in EC than in SMC but the NCX activity was greater in EC.

![Comparison of SERCA, PMCA and NCX activities EC and SMC. The relative value for each activity was computed taking the mean value in SMC as 100 %.](jcmm0011-0129-f6){#fig06}

Discussion
==========

Pig coronary artery EC and SMC differ in PMCA, SERCA and NCX whether one considers their activities, protein abundance or types of mRNA. Here, we will compare our results with observations of others in the literature and examine how properties and abundance of these transporters may relate to differences in function between EC and SMC.

This is the first report comparing the activity levels of PMCA, SERCA and NCX in EC and SMC ([Fig. 6](#fig06){ref-type="fig"}). Relative protein abundance of PMCA and NCX in the tissues has also not been reported previously. RT-PCR has been used to examine the types of mRNA expressed for PMCA and NCX in EC and SMC \[[@b1]\]. Here, we have reported that coronary artery SMC contain mRNA encoding PMCA4a, 4b and 1b. Expression of PMCA isoforms in vascular SMC has been reported but there is only limited literature on the coronary artery \[[@b1]\]. In some studies, mRNA for PMCA1b and PMCA4b were reported in SMC and in others PMCA4a mRNA was also reported to be present. There are no reports on the presence of PMCA2 or 3 in vascular SMC. We observed that EC contain predominantly PMCA1 mRNA.This was also consistent with a very low abundance of PMCA4 protein in EC in Western blots. There are no reports on Western blots using vascular EC, but with RT-PCR they have been shown to contain mRNA encoding PMCA1b and PMCA4b \[[@b19]\]. NCX1 mRNA expression has been reported in vascular EC and SMC although the exact phenotypes of the cells and proportions of different isoforms are not given \[[@b25]\]. The reports are consistent with our observations that they both contain mRNA encoding NCX1.3 and NCX1.7. Thus, these data are consistent with the literature.

This section focuses on the relationship between the type of Ca^2+^ transporters present in EC and SMC and the structure and function of the two cell types. To facilitate this discussion, key properties and our observations of SERCA, PMCA and NCX are summarized in [Table 2](#tbl2){ref-type="table"}. SERCA pump activity is lower in EC than in SMC. This is consistent with the previous observations that the SERCA inhibitor cyclopiazonic acid causes a smaller increase in \[Ca^2+^\]i in EC than in SMC. SERCA3 pump that is expressed in EC has a lower affinity for Ca^2+^ than SERCA2b, which is the only isoform in SMC ([Table 2](#tbl2){ref-type="table"}). PMCA also have high affinity for Ca^2+^ and their activity is lower in EC than in SMC. In contrast, NCX has a much lower affinity for Ca^2+^ and is present in higher levels in EC than in SMC. The lower activity of NCX in SMC is in contradiction with its ability to remove large amounts of cytosolic Ca^2+^.The larger abundance of SERCA2b in SMC is also consistent with the regulation of Ca^2+^ from around the contractile filaments that may be near cell surface and deeper in the cell. The regulation of \[Ca^2+^\]i in SMC occurs mostly by high affinity pathways that are more tightly regulated to provide the needed \[Ca^2+^\]i transients. The tighter regulation is fostered by: (1) presence of larger amounts of higher Ca^2+^ affinity systems, (2) better control of these systems: PMCA activity can be regulated by calmodulin and protein kinases, SERCA2b activity can be regulated by phospholamban and calmdulin-dependent kinase, NCX can be regulated by phospholemman, and (3) presence of limited diffusional spaces by cytoskeletal elements \[[@b24]\]. In contrast, EC are paracrine cells that secrete vasoactive agents and contain Ca^2+^-stimulated eNOS on PM or caveoli \[[@b6]\]. EC have higher activity and abundance of NCX, which has low affinity for Ca^2+^, and they do not contain phospholemman that can regulate NCX. EC contain SERCA3 that also has a low affinity for Ca^2+^ and does not contain sites for phospholamban binding or regulation by calmodulin-dependent protein kinase. We conclude that the tightly regulated Ca^2+^ removal systems in SMC are consistent with the cyclical control of contractility of the filaments and those in EC are consistent with Ca^2+^ regulation of eNOS near the cell surface \[[@b13]\].

###### 

Comparison of properties of SERCA, PMCA and NCX in vascular EC and SMC \[[@b4]\]

  **SERCA**                                                                                        
  ------------------------------------------- ---------------------------------------------------- ----------------------
  Activity level                              μmol/g protein/min: EC: 0.1--0.2 \<\< SMC: 1--2      
  Isoforms expressed                          SERCA2b in SMC                                       SERCA3 and 2b in EC
  Hill coefficient for Ca^2+^                 SERCA2b: 2                                           SERCA3: 2
  Km for Ca^2+^                               SERCA2b: 0.27 ± 0.03 μM                              SERCA3: 1.1 ± 0.1 μM
  pH optimum                                  SERCA2b: 6.8                                         SERCA3: 7.2
  Phospholamban inhibition                    SERCA2b:Yes                                          SERCA3: No
  Calmodulin-dependent kinase II activation   SERCA2b:Yes                                          SERCA3: Not known
  ROS susceptibility                          Peroxide, superoxide or peroxynitrite: SMC \>\> EC   
  **PMCA**                                                                                         
  Activity level                              μmol/g protein/min: EC: 0.3 \< SMC: 1.1              
  Isoforms expressed                          mainly PMCA1 in EC, PMCA4 and PMCA1 in SMC           
  Hill coefficient for Ca^2+^                 1                                                    
  Km for Ca^2+^                               \<0.5 μM for PMCA4, not known for PMCA1              
  **NCX**                                                                                          
  Activity level                              μmol/g protein/min: EC:1--3 \>\> SMC: 0.2--0.3       
  NCX/SERCA activity ratio                    Activity ratio: EC: 6--20 \>\> SMC: 0.14--0.2        
  Isoforms expressed                          NCX1.3 in EC and SMC and lower levels of NCX1.7      
  Hill coefficient for Ca^2+^                 1                                                    
  Km for Ca^2+^                               2.6--7 μM                                            
  Hill coefficient for Na^+^                  3                                                    
  Km for Na^+^                                25--45 mM                                            
  Phospholemman mRNA                          SMC \>\> EC                                          
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[^1]: \*The upstream primers are indicated as up and the starting position of the sequence is given. The downstream primers are indicated as dn and the end position is given.
